Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/68521
DC FieldValueLanguage
dc.contributor.authorChen, D.Y.en_US
dc.contributor.authorTzang, B.S.en_US
dc.contributor.authorChen, Y.M.en_US
dc.contributor.authorLan, J.L.en_US
dc.contributor.authorTsai, C.C.en_US
dc.contributor.authorHsu, T.C.en_US
dc.date2010zh_TW
dc.date.accessioned2014-06-11T05:56:55Z-
dc.date.available2014-06-11T05:56:55Z-
dc.identifier.issn0009-8981zh_TW
dc.identifier.urihttp://hdl.handle.net/11455/68521-
dc.description.abstractBackground: Human parvovirus B19 (B19) infection has been identified as a trigger of antiphospholipid syndrome (APS). However, the precise role of B19-VP1 unique region (VP1u) in patients with antiphospholipid syndrome remains unclear. Methods: IgM and IgG against B19-VP, and serum levels of antibodies directed against cardiolipin (CL), beta2-glycoprotein-I (beta 2GPI) and phospholipid (PhL) were determined using ELISA in 45 APS patients. Humoral responses of anti-B19-VP1u were assessed by Western blot and 819 DNA was detected by nested PCR. Absorption experiments were performed using B19-VP1u protein to determine the binding specificity of antiphospholipid antibodies (aPL). Results: One and 18 of 45 APS patients had detectable levels of anti-B19-VP IgM and anti-B19-VP IgG, indicating recent and past infection respectively. All serum samples from APS patients with diagnostic pattern DNA(-)/IgM(-)/IgG(+) had anti-B19-VP1u activity. APS patients with anti-B19-VP1u antibody had a 4-fold increased risk for recurrent vascular thrombosis compared with those without anti-B19-VP1u antibody. The binding inhibition of CL,beta 2GPI, and PhL by absorption with B19-VP1u ranged from 31.4% to 91.1%, 0.8% to 59.8% and 20.2% to 72.1% respectively. Significantly higher inhibition to beta 2GPI by B19-VP1u absorption was observed in APS patients with anti-B19-VP1u antibody than in those without anti-B19-VP1u antibody. Conclusions: We show a close association of B19 infection with aPL production and suggest B19-VP1u may be of pathogenetic importance in some patients with APS. (C) 2010 Elsevier B.V. All rights reserved.en_US
dc.language.isoen_USzh_TW
dc.relationClinica Chimica Actaen_US
dc.relation.ispartofseriesClinica Chimica Acta, Volume 411, Issue 15-16, Page(s) 1084-1089.en_US
dc.relation.urihttp://dx.doi.org/10.1016/j.cca.2010.04.004en_US
dc.subjectHuman parvovirus B19 (B19)en_US
dc.subjectVP1 unique region protein (VP1u)en_US
dc.subjectAntiphospholid antibody (aPL)en_US
dc.subjectAntiphospholipid syndrome (APS)en_US
dc.subjectSystemicen_US
dc.subjectlupus erythematosus (SLE)en_US
dc.subjectsystemic-lupus-erythematosusen_US
dc.subjectminor capsid proteinen_US
dc.subjectb19 infectionen_US
dc.subjectvp1en_US
dc.subjectuniqueen_US
dc.subjectphospholipase a(2)en_US
dc.subjectlinear epitopesen_US
dc.subjectdiseaseen_US
dc.subjectinductionen_US
dc.subjectcofactoren_US
dc.subjectclassificationen_US
dc.titleThe association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndromeen_US
dc.typeJournal Articlezh_TW
dc.identifier.doi10.1016/j.cca.2010.04.004zh_TW
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextno fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en_US-
item.openairetypeJournal Article-
Appears in Collections:期刊論文
Show simple item record
 

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.